Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

102. Alogliptin/metformin (Vipdomet®)

Alogliptin/metformin (Vipdomet®) Alogliptin/metformin (Vipdomet®) Alogliptin/metformin (Vipdomet®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Alogliptin/metformin (Vipdomet®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales (...) Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 3314. 2014 Authors' conclusions Alogliptin/metformin (Vipdomet®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin/metformin (Vipdomet®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: • As an adjunct to diet and exercise to improve glycaemic

Health Technology Assessment (HTA) Database.2015

104. Systematic review: Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment

Systematic review: Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment Article Text Aetiology/Harm Systematic review Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal

Evidence-Based Medicine (Requires free registration)2015

105. Metformin to reduce weight gain and metabolic disturbance in schizophrenia

Metformin to reduce weight gain and metabolic disturbance in schizophrenia Metformin to reduce weight gain and metabolic disturbance in schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin to reduce weight gain and metabolic disturbance in schizophrenia Article Text Pharmacological interventions Metformin to reduce weight gain and metabolic disturbance in schizophrenia Guy Faulkner , Mark Duncan Statistics from Altmetric.com No Altmetric data available for this article. ABSTRACT FROM: Mizuno Y, Suzuki T, Nakagawa A, et al

Evidence-Based Mental Health2015

106. Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin

Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you (...) and metformin: metformin (plus insulin when required) performs better than insulin Article Text Therapeutics/Prevention Systematic review with meta analysis In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Dana Carroll , Kristi W Kelley Statistics from Altmetric.com No Altmetric data available for this article. Commentary on : Balsells M , Garia-Patterson A , Solà I , et al

Evidence-Based Medicine (Requires free registration)2015

108. Flowchart: Intrapartum management for gestational diabetes mellitus requiring Insulin and/or Metformin

Flowchart: Intrapartum management for gestational diabetes mellitus requiring Insulin and/or Metformin Document Number: F15.33--2-V1-R20 Department of Health Queensland Clinical Guidelines State of Queensland (Queensland Health) 2015 http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Queensland Clinical Guidelines, Guidelines@health.qld.gov.au Intrapartum management for GDM requiring Insulin and/or Metformin Metformin • Cease when labour established Insulin • Cease when labour (...) established • If morning IOL (and labour not established) o Eat breakfast and give usual rapid acting Insulin o Omit morning long or intermediate acting Insulin • If afternoon IOL (and labour not established) o Give usual mealtime and bedtime Insulin GDM Insulin or Metformin Mode of birth? Day before procedure • Cease Metformin 24 hours prior to procedure • Give usual Insulin the night before procedure Day of morning procedure • Fast from 2400 hours • Omit morning Insulin Monitor BGL 2/24 > 7.0 : greater

Queensland Health2015

109. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses

Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses Zhang Q, Dou J, Lu J CRD summary This review (...) concluded that sodium-glucose linked transporter 2 (SGLT2) inhibitors plus metformin could be effective for patients with type 2 diabetes, based on glycaemic control, body weight and blood pressure. The authors' conclusions reflect the short-term evidence (up to 24 weeks), but the longer term data (one year and two years) were less reliable. Authors' objectives To assess sodium-glucose linked transporter 2 (SGLT2) inhibitors, with metformin, for the management of patients with type 2 diabetes under

DARE.2014

110. Alogliptin/metformin (Vipdomet) - treatment of adult patients aged 18 years and older with type 2 diabetes mellitus

Alogliptin/metformin (Vipdomet) - treatment of adult patients aged 18 years and older with type 2 diabetes mellitus %PDF-1.4 %���� 61 0 obj > endobj 88 0 obj >/Filter/FlateDecode/ID[ ]/Index[61 48]/Info 60 0 R/Length 117/Prev 542494/Root 62 0 R/Size 109/Type/XRef/W[1 3 1]>>stream h�bbd```b``z "���0ɚ f�I �0� �� fO���z@$�W�"��H�8��-�q����@�.���Kf20�y����N��#� �h endstream endobj startxref 0 %%EOF 108 0 obj >stream h�b```� � �y " ��ea���Ф%����8���������G�P��� ̠p@ �!����y�D�L �8m�T���jh��\u```�b

All Wales Medicines Strategy Group2014

111. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects

Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects Prescrire IN ENGLISH - Spotlight ''Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects '', 1 November 2014 {1} {1} {1} | | > > > Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects Spotlight Every month (...) , the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects FEATURED REVIEW The efficacy of metformin in type 2 diabetes is still thinly documented in 2014. However, an abundance of data is now available on its adverse effects. The evidence is relatively weak

Prescrire2014

112. Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin 25352655 2015 02 26 2015 08 27 2015 02 26 1935-5548 38 3 2015 Mar Diabetes care Diabetes Care Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single (...) addition of saxagliptin or dapagliflozin to metformin. 376-83 10.2337/dc14-1142 This study compared the efficacy and safety of dual add-on of saxagliptin plus dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 diabetes poorly controlled with metformin. This was a double-blind trial in adults with HbA1c ≥8.0% and ≤12.0% (64-108 mmol/mol), randomized to saxagliptin (SAXA) (5 mg/day) plus dapagliflozin (DAPA) (10 mg/day; n = 179), or SAXA (5 mg/day) and placebo (n

EvidenceUpdates2014

113. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. BACKGROUND: Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and efficacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated (...) patients with uncontrolled type 2 diabetes. METHODS: We did a phase 3, randomised, open-label, parallel-group study at 62 sites in nine countries between June 20, 2012, and Nov 25, 2013. Patients with inadequately controlled type 2 diabetes receiving metformin (≥1500 mg/day), aged 18 years or older, with glycated haemoglobin (HbA1c) 7·0% or greater (≥53 mmol/mol) and 10·0% or lower (≤86 mmol/mol), and body-mass index 45 kg/m(2) or lower were randomly assigned to receive once-weekly dulaglutide (1·5 mg

Lancet2014

115. Dapagliflozin + metformin (Xigduo) - in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control

Dapagliflozin + metformin (Xigduo) - in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control

Scottish Medicines Consortium2014

116. Linagliptin/metformin (Jentadueto) - for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy)

Linagliptin/metformin (Jentadueto) - for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) %PDF-1.5 %���� 84 0 obj > endobj 105 0 obj >/Filter/FlateDecode/ID[ ]/Index[84 44]/Info 83 0 R/Length 95/Prev 202915/Root 85 0 R/Size 128/Type/XRef/W[1 2 1]>>stream h�bbd``b`Z $���^ �~H0IԃX�AD���Z".��N@�+�M D��_A,] �$�O��;�3012 >stream h�b``f``�a��2�F fa�h@�b�!�t�L� �(3p�0�1,h�W�Pa�T0+�����y�W`&23fBLf9 7���Y�D�Q ��dO endstream

All Wales Medicines Strategy Group2014

118. Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials

Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic (...) review of randomized controlled trials Gao W, Dong J, Liu J, Li Y, Liu F, Yang L, Zhou X, Liao L CRD summary The authors concluded that compared with equal-dosage metformin monotherapy, initial combination of metformin and dipeptidyl peptidase-IV inhibitors was more effective in type 2 diabetes glycaemic control without additional risk of adverse events. Although the authors’ conclusions reflect the results, the varied patients and treatments plus the lack of reporting of trial quality mean

DARE.2014

120. [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V. [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 220. 2014 Final publication URL Indexing Status Subject indexing assigned

Health Technology Assessment (HTA) Database.2014